FY2025 EPS Estimates for MariMed Lowered by Noble Financial

MariMed Inc. (OTCMKTS:MRMD) – Stock analysts at Noble Financial reduced their FY2025 earnings estimates for MariMed in a research note issued on Monday, May 12th. Noble Financial analyst J. Gomes now forecasts that the company will earn ($0.04) per share for the year, down from their previous estimate of ($0.01). Noble Financial currently has a “Strong-Buy” rating on the stock. Noble Financial also issued estimates for MariMed’s FY2026 earnings at ($0.02) EPS.

MariMed (OTCMKTS:MRMD) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $37.96 million during the quarter, compared to the consensus estimate of $38.33 million. MariMed had a negative net margin of 10.97% and a negative return on equity of 2.75%.

MariMed Stock Up 0.6%

OTCMKTS MRMD opened at $0.09 on Wednesday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.55 and a quick ratio of 0.73. MariMed has a fifty-two week low of $0.07 and a fifty-two week high of $0.29. The stock has a market capitalization of $33.23 million, a PE ratio of -2.14 and a beta of 3.15. The business has a fifty day moving average price of $0.10 and a two-hundred day moving average price of $0.12.

About MariMed

MariMed Inc engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand.